PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 12,572 Shares

Posted by on May 16th, 2026

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) CEO Matthew Klein sold 12,572 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $72.95, for a total value of $917,127.40. Following the completion of the sale, the chief executive officer directly owned 393,998 shares of the company’s stock, valued at $28,742,154.10. This trade represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

PTC Therapeutics Stock Down 1.7%

Shares of PTCT opened at $71.47 on Friday. PTC Therapeutics, Inc. has a 52-week low of $43.17 and a 52-week high of $87.50. The company has a market capitalization of $5.93 billion, a PE ratio of -30.67, a price-to-earnings-growth ratio of 13.56 and a beta of 0.53. The stock has a fifty day simple moving average of $68.57 and a two-hundred day simple moving average of $72.32.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.42. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 22.58%.The business had revenue of $272.55 million during the quarter, compared to the consensus estimate of $217.42 million. During the same period last year, the company earned $10.04 EPS. The company’s revenue for the quarter was up 43.5% on a year-over-year basis. As a group, equities analysts anticipate that PTC Therapeutics, Inc. will post 0.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PTC Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of PTCT. Jefferies Financial Group Inc. purchased a new position in PTC Therapeutics during the 3rd quarter valued at about $97,252,000. Janus Henderson Group PLC boosted its holdings in PTC Therapeutics by 28.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock valued at $368,587,000 after acquiring an additional 1,077,776 shares during the period. State Street Corp boosted its holdings in PTC Therapeutics by 34.2% during the 4th quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock valued at $319,497,000 after acquiring an additional 1,071,343 shares during the period. Toronto Dominion Bank boosted its holdings in PTC Therapeutics by 27.5% during the 4th quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock valued at $314,339,000 after acquiring an additional 891,690 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in PTC Therapeutics by 4,013.1% during the 4th quarter. BNP Paribas Financial Markets now owns 828,662 shares of the biopharmaceutical company’s stock valued at $62,945,000 after acquiring an additional 808,515 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of PTC Therapeutics in a report on Friday, February 20th. Raymond James Financial assumed coverage on PTC Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $108.00 price target for the company. Morgan Stanley reiterated an “overweight” rating and set a $94.00 price target on shares of PTC Therapeutics in a report on Friday, May 8th. Wells Fargo & Company increased their price target on PTC Therapeutics from $86.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, Barclays reiterated an “overweight” rating and set a $120.00 price target on shares of PTC Therapeutics in a report on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $88.36.

Check Out Our Latest Research Report on PTC Therapeutics

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

Featured Stories

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.